Key result
Sequential delivery of rapid ECP and sustained IL-4 reduces infarct size and boosts post-MI functional recovery.
Why the study?
Eosinophils protect the heart from post-MI injury via eosinophil cationic protein (ECP) and interleukin-4 (IL-4), motivating the engineering and optimization of a cell-free therapy through regulated sequential delivery of ECP and IL-4.
Does sequential intrapericardial delivery of rapid-release eosinophil cationic protein followed by sustained-release interleukin-4 improve cardiac function and limit infarct size in mice with myocardial infarction?
Does sequential intrapericardial delivery of rapid-release eosinophil cationic protein followed by sustained-release interleukin-4 improve cardiac function and limit infarct size in mice with myocardial infarction?
In a mouse model of myocardial infarction, sequential intrapericardial delivery of rapid-release eosinophil cationic protein and sustained-release interleukin-4 via thermosensitive hydrogel microspheres orchestrated functional neovessel formation and improved cardiac recovery, offering a potential cell-free alternative to eosinophil therapy.
Answers are grounded in this paper and cite their sources.
Sequential ECP/IL-4 hydrogel delivery attenuates murine post-MI injury; extends eosinophil mechanisms but leaves open clinical translation.
Eosinophils protect heart from post-myocardial infarction (MI) injury via cationic protein (ECP) and interleukin-4 (IL-4). Here we engineered and optimized a cell-free therapy for MI via regulated delivery of ECP and IL-4. Pluronic F127 thermosensitive hydrogels embedded with gelatin methacryloyl microspheres (GMs) were constructed for sequential ECP and IL-4 delivery. Immediately following MI, mice received an intrapericardial injection of therapeutic formulations. At 3 days post-MI, codelivery of ECP and IL-4 limited infarct size and preserved cardiac function. Rapid ECP release followed by sustained IL-4 release (IL-4@GM + ECP) yielded the most favorable outcomes with attenuated cardiomyocyte apoptosis and enhanced M2 macrophage contents in post-MI hearts. At 28 days post-MI, IL-4@GM + ECP exhibited robust cardiac functional recovery and cardiac geometry maintenance with minimal fibrotic scarring. Microfil perfusion imaging revealed that IL-4@GM + ECP enhanced angiogenesis with abundant perfused neovessels in the infarcts. Matrigel plug assays confirmed that codelivery of ECP and IL-4 yielded mature and tight vessel structures with CD31 + endothelial cell (EC) lumens surrounded by α-SMA + smooth muscle cells (SMCs) and PDGFR-β + pericytes. Mechanistic studies demonstrated that ECP induced angiogenesis by enhancing EC proliferation, migration, and cellular junctions. Conversely, IL-4 disrupted endothelial junctions but enhanced SMC migration to stabilize nascent endothelium. Sequential delivery of ECP and IL-4 helps generate functional neovessels. The therapeutic efficacy of IL-4@GM + ECP in MI was validated in eosinophil-deficient ΔdblGATA mice. In summary, rapid ECP release, followed by sustained IL-4 release effectively improved cardiac function post-MI by orchestrating neovessel formation, providing a cell-free alternative to eosinophil-based cell therapy for MI.
No takes yet. Share an insight, caveat, or question.
Chu et al. (2026) studied Myocardial infarction. Intrapericardial injection of Pluronic F127 thermosensitive hydrogels with gelatin methacryloyl microspheres for rapid eosinophil cationic protein (ECP) and sustained interleukin-4 (IL-4) release (IL-4@GM + ECP) was evaluated on Infarct size, cardiac functional recovery, cardiac geometry maintenance, and angiogenesis. Sequential delivery of rapid ECP and sustained IL-4 (IL-4@GM + ECP) limited infarct size at 3 days and improved cardiac functional recovery and angiogenesis at 28 days post-MI in mice.
Synapse has enriched 10 related papers. Consider them for comparative context: